Peptide Comparison
Liraglutide vs Survodutide
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Liraglutide has stronger documented evidence (FDA-Approved) than Survodutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. Survodutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Liraglutide | Survodutide | |
|---|---|---|
| Class | GLP-1 receptor agonist | GLP-1/glucagon dual agonist |
| Drug class | Metabolic & Weight | Metabolic & Weight |
| Mechanism | GLP-1R agonist; albumin-binding fatty acid extends half-life | Dual GLP-1/glucagon receptor activation |
| Route | SC injection | SC injection |
| Half-life | ~13 hrs | Long-acting weekly |
| Dosage (research) | 0.6 mg SC daily (Victoza/Saxenda label starting dose, escalate weekly by 0.6 mg to 1.8 mg/day for T2D per Victoza or 3 mg/day for obesity per Saxenda label) | 0.6-4.8 mg SC weekly |
| Evidence tier | FDA-Approved | Phase 3 |
| Research depth | 321 indexed | 126 indexed |
| Availability | Prescription | Investigational |
| Reported risks | Nausea; vomiting; pancreatitis; gallbladder disease; thyroid C-cell tumor warning | GI side effects; injection reactions |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Liraglutide or Survodutide?
Liraglutide has stronger documented evidence (FDA-Approved) than Survodutide (Phase 3) while both occupy the glp-1 class. When clinical-evidence tier is the deciding factor, Liraglutide is the safer pick. Survodutide may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between Liraglutide and Survodutide?
Liraglutide is classed as GLP-1 receptor agonist; Survodutide is classed as GLP-1/glucagon dual agonist. Reported mechanism: Liraglutide, GLP-1R agonist; albumin-binding fatty acid extends half-life; Survodutide, Dual GLP-1/glucagon receptor activation. Reported half-life: Liraglutide, ~13 hrs; Survodutide, Long-acting weekly. Routes in published studies: Liraglutide, SC injection; Survodutide, SC injection.
Which has stronger evidence, Liraglutide or Survodutide?
Liraglutide has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Liraglutide is graded FDA-Approved, with 64 cited sources on its reference page and 321 indexed studies. Survodutide is graded Phase 3, with 33 cited sources on its reference page and 126 indexed studies.
Which is more accessible, Liraglutide or Survodutide?
Liraglutide is FDA-approved and Survodutide is not. Catalog status: Liraglutide, Prescription; Survodutide, Investigational.
Are Liraglutide and Survodutide ever combined?
Liraglutide and Survodutide appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…